Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation

H. Nakasone, T. Fukuda, J. Kanda, Takehiko Mori, S. Yano, T. Kobayashi, K. Miyamura, T. Eto, H. Kanamori, K. Iwato, N. Uchida, S. Mori, T. Nagamura-Inoue, T. Ichinohe, Y. Atsuta, T. Teshima, M. Murata

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number4
DOIs
Publication statusPublished - 2015 Apr 4

Fingerprint

Cell Transplantation
Transplants
Japan
Multivariate Analysis
Skin
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. / Nakasone, H.; Fukuda, T.; Kanda, J.; Mori, Takehiko; Yano, S.; Kobayashi, T.; Miyamura, K.; Eto, T.; Kanamori, H.; Iwato, K.; Uchida, N.; Mori, S.; Nagamura-Inoue, T.; Ichinohe, T.; Atsuta, Y.; Teshima, T.; Murata, M.

In: Bone Marrow Transplantation, Vol. 50, No. 4, 04.04.2015, p. 559-565.

Research output: Contribution to journalArticle

Nakasone, H, Fukuda, T, Kanda, J, Mori, T, Yano, S, Kobayashi, T, Miyamura, K, Eto, T, Kanamori, H, Iwato, K, Uchida, N, Mori, S, Nagamura-Inoue, T, Ichinohe, T, Atsuta, Y, Teshima, T & Murata, M 2015, 'Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation', Bone Marrow Transplantation, vol. 50, no. 4, pp. 559-565. https://doi.org/10.1038/bmt.2014.293
Nakasone, H. ; Fukuda, T. ; Kanda, J. ; Mori, Takehiko ; Yano, S. ; Kobayashi, T. ; Miyamura, K. ; Eto, T. ; Kanamori, H. ; Iwato, K. ; Uchida, N. ; Mori, S. ; Nagamura-Inoue, T. ; Ichinohe, T. ; Atsuta, Y. ; Teshima, T. ; Murata, M. / Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 4. pp. 559-565.
@article{de150d99d68440628a1cc939753fe61b,
title = "Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation",
abstract = "The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39{\%} in TBI-MAC, 35{\%} in TBI-RIC and 32{\%} in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.",
author = "H. Nakasone and T. Fukuda and J. Kanda and Takehiko Mori and S. Yano and T. Kobayashi and K. Miyamura and T. Eto and H. Kanamori and K. Iwato and N. Uchida and S. Mori and T. Nagamura-Inoue and T. Ichinohe and Y. Atsuta and T. Teshima and M. Murata",
year = "2015",
month = "4",
day = "4",
doi = "10.1038/bmt.2014.293",
language = "English",
volume = "50",
pages = "559--565",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation

AU - Nakasone, H.

AU - Fukuda, T.

AU - Kanda, J.

AU - Mori, Takehiko

AU - Yano, S.

AU - Kobayashi, T.

AU - Miyamura, K.

AU - Eto, T.

AU - Kanamori, H.

AU - Iwato, K.

AU - Uchida, N.

AU - Mori, S.

AU - Nagamura-Inoue, T.

AU - Ichinohe, T.

AU - Atsuta, Y.

AU - Teshima, T.

AU - Murata, M.

PY - 2015/4/4

Y1 - 2015/4/4

N2 - The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.

AB - The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84926408530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926408530&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.293

DO - 10.1038/bmt.2014.293

M3 - Article

C2 - 25531281

AN - SCOPUS:84926408530

VL - 50

SP - 559

EP - 565

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -